At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09926 AKESO
Market Closed 04-02 16:08:21
140.500
+1.300
+0.93%
High141.800Low137.300Vol9.85M
Open140.000D1 Closing139.200Amplitude3.23%
Mkt Cap129.40BTradable Cap129.40BTotal Shares921.00M
T/O1.37BT/O Rate1.07%Tradable Shares921.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026
Stock News  ·  04-03 10:54
China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026
Stock Track | AKESO Soars 5.53% Intraday on Positive Phase III Quality-of-Life Results for Ivonescimab
Stock Track  ·  04-01
Stock Track | AKESO Soars 5.53% Intraday on Positive Phase III Quality-of-Life Results for Ivonescimab
Akeso says ivonescimab improves quality of life vs pembrolizumab in Phase III NSCLC study
Reuters  ·  04-01
Akeso says ivonescimab improves quality of life vs pembrolizumab in Phase III NSCLC study
Mainland Investors Divest HK$2.47 Billion from Hong Kong Market, Offloading ETFs and Oil Stocks While Boosting Tencent Holdings
Stock News  ·  03-30
Mainland Investors Divest HK$2.47 Billion from Hong Kong Market, Offloading ETFs and Oil Stocks While Boosting Tencent Holdings
Akeso (SEHK:9926) FY 2025 Loss Deepens Despite 2H Revenue Growth Challenging Bullish Narratives
Simply Wall St.  ·  03-28
Akeso (SEHK:9926) FY 2025 Loss Deepens Despite 2H Revenue Growth Challenging Bullish Narratives
Akeso Widens Loss in 2025; Shares Climb 3%
MT Newswires Live  ·  03-27
Akeso Widens Loss in 2025; Shares Climb 3%
Press Release: Akeso Reports Full-Year 2025 Financial Results
Dow Jones  ·  03-27
Press Release: Akeso Reports Full-Year 2025 Financial Results
Stock Track | AKESO Plummets 5.42% Intraday as FY2025 Loss Widens to CNY 1.1 Billion Despite Revenue Growth
Stock Track  ·  03-27
Stock Track | AKESO Plummets 5.42% Intraday as FY2025 Loss Widens to CNY 1.1 Billion Despite Revenue Growth
Asian Growth Companies Insiders Are Eager To Own
Simply Wall St.  ·  03-27
Asian Growth Companies Insiders Are Eager To Own
3 Asian Stocks Estimated To Be Up To 44.5% Below Intrinsic Value
Simply Wall St.  ·  03-27
3 Asian Stocks Estimated To Be Up To 44.5% Below Intrinsic Value
BRIEF-Akeso FY Revenue RMB 3,056.3 Million
Reuters  ·  03-26
BRIEF-Akeso FY Revenue RMB 3,056.3 Million
AKESO Reports Annual Revenue Surge of 43.9% to RMB 30.56 Billion
Stock News  ·  03-26
AKESO Reports Annual Revenue Surge of 43.9% to RMB 30.56 Billion
Akeso FY2025 revenue rises to CNY 3.1 billion; annual loss widens to CNY 1.1 billion
Reuters  ·  03-26
Akeso FY2025 revenue rises to CNY 3.1 billion; annual loss widens to CNY 1.1 billion
Akeso - FY Loss Attributable RMB1.11 Bln
THOMSON REUTERS  ·  03-26
Akeso - FY Loss Attributable RMB1.11 Bln
Akeso Advances Next Generation Oncology Pipeline With New Trial Clearances
Simply Wall St.  ·  03-26
Akeso Advances Next Generation Oncology Pipeline With New Trial Clearances
China NMPA CDE clears Akeso Phase II trials for AK146D1 and AK138D1
Reuters  ·  03-25
China NMPA CDE clears Akeso Phase II trials for AK146D1 and AK138D1
Earning Preview: AKESO this quarter’s revenue is expected to increase by 0%, and institutional views are Neutral
Earnings Agent  ·  03-19
Earning Preview: AKESO this quarter’s revenue is expected to increase by 0%, and institutional views are Neutral
Akeso (9926.HK) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results
Bulletin Express  ·  03-16
Akeso (9926.HK) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results
Akeso board to review and approve full-year results
Reuters  ·  03-16
Akeso board to review and approve full-year results
AKESO Shares Climb Over 4% Again Following Clinical Trial Approval for First Trispecific Antibody
Stock News  ·  03-16
AKESO Shares Climb Over 4% Again Following Clinical Trial Approval for First Trispecific Antibody
No data available

Introduction

Company Name.
AKESO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
Issue price:
--